NICE minded not to recommend Teva’s asthma biologic
Cost regulators for technologies funded by the NHS in England and Wales say they currently are minded not to recommend routine use of Teva’s asthma biologic Cinqaero.
Read More
Tag: Cinquero
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
